Role of oral tranexamic acid to decrease blood loss during myoma excision surgery

Prophylactic use of oral tranexamic acid to decrease blood loss during myomectomy: a randomised contolled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/04/052073

Enrollment

Registered

2023-04-27

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N998- Other intraoperative and postprocedural complications and disorders of genitourinary system

Interventions

Intervention1: oral tranexemic acid group: Group D patients will receive oral tranexamic acid 1gm 2 hours before surgery. Control Intervention1: oral placebo group: Group C patients will receive oral

Eligibility

Inclusion criteria

Inclusion criteria: ASA physical status 1 and 2, undergoing laparoscopic myomectomy surgeries

Exclusion criteria

Exclusion criteria: Patients with medical history of (thromboembolic disease, ischemic heart disease, malignancy, hematuria, liver or kidney disease, or subarachnoid hemorrhage), parturients, nursing mothers, hormonal contraception, on drugs affecting coagulation(factor IX complex concentrates, Anti-inhibitor coagulant concentrates and trans-retinoic acid) and hypersensitivity to tranexamic Acid

Design outcomes

Primary

Measure	Time frame
compare intraoperative blood loss between groupsTimepoint: Intraoperative period	—

Secondary

Measure	Time frame
compare the drop in postoperative hemoglobin, requirement of blood transfusions, and any complications associated with the use of tranexamic acid.Timepoint: Intraoperative period	—

Countries

India

Contacts

Public ContactSejibelvin

Amrita Institute of medical Sciences

nituveesundeep@gmail.com09495962020

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026